The Beyond Tomorrow Podcast with Julian Issa

Our mission at Beyond Tomorrow is to build a world where anyone can flourish. For the first time, AI and longevity are making that a possibility. Every conversation & debate is about bringing that reality one step closer. Hit follow to join us on the journey.

Julian

Afleveringen

Beyond Tomorrow New Trailer

3 november 2026 · 1 min
Afspelen

I have a strong conviction that the next chapter in the human story will bring incredible opportunity and abundance to us all if we take the right steps. At Beyond Tomorrow, we want to help steward that transition. After all, our mission is to help build a world where anyone can flourish. Thank you for being part of our journey Lees meer

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
AI EXPERTS REVEAL: It’s Too Late! We Can't Stop What's Coming

30 oktober 2026 · 1 uur 30 min
Afspelen

Everyone agrees we can’t pause AI. So what do we do instead? Lees meer

This episode is brought to you by AgelessRx, where aging becomes a puzzle that can be solved. The mission is to help you live longer and healthier by adding more life to your years through science-backed solutions and personalized care. Learn more at http://agelessrx.com/beyond-tomorrow.

Five people who think about AI for a living sit down for a rapid-fire debate, and the host throws a handful of big statements at them. First up: can we, or should we, pause AI? Almost nobody says yes, and the more interesting part is what they’d do instead. Some want to slow the frontier, some want to shape it as it goes, and one is trying to seed a beneficial AGI before someone else builds a worse one.

From there the panel gets into recursive self-improvement and whether you can keep an AI’s goals stable, whether AI will widen the gap between rich and poor (and rich and poor countries), and who foots the bill when jobs disappear. Then comes the question of why experts and the public see AI so differently. Media, culture, and trust all take some blame. The last stretch compares a Manhattan Project approach with open, decentralized AGI, and everyone gets to say the one thing they think the world needs right now, plus a parting sentence.

Key Takeaways

Nearly everyone calls a pause a non-starter: “AI” is too fuzzy to define, and a pause would just push work underground

Keeping an AI’s goals stable while it rewrites itself may be a solvable engineering problem, but not everyone agrees that’s even desirable

On inequality, the panel splits between “it’s already happening” and “the floor keeps rising”

Public opinion on AI is shaped more by culture and media than by the tech itself

The alternative to corporate control or a government Manhattan Project: open, decentralized AGI, in the spirit of Linux

Meet the Panelists:

Ben Goertzel is the CEO of SingularityNET and Executive Chairman & Chief Scientist of BGI Labs who po…
ROBOTICS PROFESSOR: "AI Is Becoming Self-Aware! Here’s the Biggest Danger!"

22 oktober 2026 · 1 uur 22 min
Afspelen

Is “AI will destroy humanity” a real risk, or a story we tell ourselves because we haven’t done the hard engineering? Lees meer

This episode is brought to you by AgelessRx, where aging becomes a puzzle that can be solved. The mission is to help you live longer and healthier by adding more life to your years through science-backed solutions and personalized care. Learn more at agelessrx.com/beyond-tomorrow.

This conversation opens with a simple question to roboticist Hod Lipson, the mind behind Emo: does he feel like a villain? His answer is honest. He’s both excited and terrified, like someone being told an alien race is about to arrive and being asked whether to welcome them. From there, the discussion turns to why robot faces are so hard to build, and why he thinks the moment a robot genuinely smiles back at you will change how we connect with machines.

Then it gets into the harder questions. Hod is firm that AI won’t wipe out humanity, and he’s challenged more than once on superintelligence, on who benefits from the fear, and on whether nested sandboxes and “AI cops” can really keep us safe. The conversation also explores what it means for a robot to be self-aware, robots that repair and even “eat” each other, why he worries about kids and students whose best friend is an AI, and how any of us finds meaning when machines can do almost everything. It closes with the best advice he’s ever been given.

About Hod Lipson

Hod Lipson is a roboticist and AI researcher who leads work on Emo, a robot focused on realistic facial expression and lip movement. His research spans robot self-awareness, self-repairing and self-reproducing robots, and AI in agriculture.

⏱ Timestamps

00:00 Intro

00:08 Do You Feel Like a Villain? The AI Disaster Question

00:59 Robot Faces Are Next

03:49 Why Do We Need a Robot Face?

05:58 Robots That Look More Human-Like

07:50 Are You Scared?

08:42 “We Earned It” as a Human Race

10:40 The Benefits of Developing AI

15:07 Could AI Go Against Us?

…
BT Clip: Exercise Scientist on Weight Loss Drugs (Mike Israetel)

20 oktober 2026 · 8 min
Afspelen

Do we really know enough about GLP-1 drugs? Lees meer

Mike Israetel breaks down the risks and trade-offs, from anhedonia and calorie-deprived diets to cognitive distortion and the myth of a “zero-harm” default.

Watch the full episode here: https://open.spotify.com/episode/4iHXkGzLvxSU87rzOHNvlq?si=361782122faa4ea9

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
4 Longevity Legends Debate Each Other About Human Flourishing

15 oktober 2026 · 1 uur 3 min
Afspelen

What if the fastest way to a longer life isn't a miracle drug, but a wartime mentality against aging? Lees meer

This episode is brought to you by AgelessRx, where aging becomes a puzzle that can be solved. The mission is to help you live longer and healthier by adding more life to your years through science-backed solutions and personalized care. Learn more at agelessrx.com/beyond-tomorrow.

Curious about quantum energy wellness? Check out Leela Quantum Tech. Check out https://leelaq.com/

On this episode of Beyond Tomorrow, four heavyweights of the longevity field take a rapid-fire statement format and turn it into a real debate. Aubrey de Grey, Alex Zhavoronkov (Insilico Medicine), George Church (Harvard Medical School), Michael Ringel (Life Biosciences) argue over whether hype helps or hurts the field, and when longevity escape velocity, the point where damage is repaired faster than it accumulates, might actually arrive. Aubrey puts it at a 50/50 chance within 12 to 15 years. Alex says 20 to 50 years and doubts drugs alone can get there. Michael pushes back on the idea of infinite lifespans entirely, while George suggests we may already be gaining years without the evidence to prove it.

From there the panel digs into the FDA's new interest in aging, why the TAME metformin trial never opened the floodgates, and whether AI will really shrink clinical timelines. George cites a gene therapy that reached a patient in seven months, while Alex, running many programs, argues that biology still moves at the speed of traffic. The back half covers biohacking and early adopters, the gap between everyday "longevity" and longevity biotechnology, the science of epigenetic reprogramming, what could happen by the XPRIZE Healthspan deadline in 2030, and what each panelist thinks the "ChatGPT moment" for longevity will look like.

About the Panelists

Aubrey de Grey has spent his entire career in the nonprofit sector, coined the term longevity escape velocity, and has been signed up with…
BT Clip: Can We Escape The Simulation? (Roman Yampolskiy)

13 oktober 2026 · 11 min
Afspelen

Are we living in a simulation? Lees meer

Dr. Roman Yampolskiy explains how scientists run experiments inside simulations, why boxing AI may not hold, and what it would mean if AI breaks out of its safe environment, or if humanity escapes its own.

Watch the full episode here: https://open.spotify.com/episode/2R7oKzVSOWTR5079TYrZsg?si=7fd6c78a016a4b67

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
MIT Professor & AI Doomer Admits He Was WRONG (Ramesh Raskar)

8 oktober 2026 · 1 uur 9 min
Afspelen

What happens when millions of people hand their lives to AI agents, and nobody has built the rules of the road? Lees meer

This episode is brought to you by AgelessRx, where aging becomes a puzzle that can be solved. The mission is to help you live longer and healthier by adding more life to your years through science-backed solutions and personalized care. Learn more at agelessrx.com/beyond-tomorrow.

MIT Media Lab professor Ramesh Raskar argues the real danger isn't the AI engine, it's agents with no governance. His case: decentralize AI so billions of people run their own agents, and build the licences, inspections and audit trails agents need, instead of trusting a few labs to make the engine safe. His P(doom) has fallen from 90% to under 10%.

The conversation covers what an AI agent actually is, personal agents like Dot, Muse, Instinct and CC, the DRIVE framework for gradually trusting an agent, why there's no such thing as "zero-shot AGI," the OpenAI and Hugging Face incident, prompt injection, and the shift from an attention economy to an intention economy. One question runs through it all: can we get the benefits of AI agents without handing control to a handful of companies, or to the agents themselves? Ramesh's answer: don't just build better engines, build the roads, the rules and the governance.

Key Takeaways

An agent is an LLM in a loop with tools: the LLM is the engine, the agent is the car, the internet is the road.

Build trust with DRIVE (Discover, Request, Instruct, Venture, Execute), and start with reversible tasks, no credit cards.

Decentralized agents shrink the blast radius, which is why Ramesh's P(doom) has dropped sharply.

Cost is the bottleneck: running an agent per user costs far more than serving a social media user, so expect revenue-share deals.

Prompt injection is the top risk because LLMs can't separate commands from content. Agents need licences, inspection stickers and audit trails.

About Ramesh Raskar

Ramesh Raskar is a professor at …
BT Clip: Scientist Exposes The Dangers of AI Super Intelligence (Roman Yampolskiy)

6 oktober 2026 · 11 min
Afspelen

AI safety researcher Roman Yampolskiy breaks down his P(doom) estimate and why he believes artificial superintelligence could be a death sentence for humanity if development keeps moving this fast. His warning isn't anti-AI — it's a case for keeping AI as a tool we control, not a replacement for human judgment. Lees meer

Watch the full episode: https://open.spotify.com/episode/2R7oKzVSOWTR5079TYrZsg?si=302dfca33e9f4c04

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Ex-DeepMind Scientist WARNS: Why We Still Can’t Trust Today’s AI

2 oktober 2026 · 1 uur 43 min
Afspelen

Is "AI is dangerous" a warning, or the world's best marketing line? Lees meer

This episode is brought to you by AgelessRx, where aging becomes a puzzle that can be solved. The mission is to help you live longer and healthier by adding more life to your years through science-backed solutions and personalized care. Learn more at agelessrx.com/beyond-tomorrow.

On this episode of Beyond Tomorrow, I sit down with Thore Graepel, co-creator of AlphaGo and former researcher at Google DeepMind. I asked him straight up how close we are to superintelligence, and his answer surprised me: there won't be a single moment we can point to, and he argues human organizations like companies already count as a form of superintelligence. We get into why he thinks "AI will destroy humanity" is the biggest myth in the field, the near-term risks he does take seriously, and why I pushed him on the incentives behind the AI safety messaging coming from the labs.

From there we go deep on his core technical argument: that today's transformers are black boxes that mix knowledge and reasoning in the same weights, and that scaling alone will never make them trustworthy. He lays out a different approach built on explicit beliefs, hypotheses and evidence, and I found it one of the clearest explanations of AI transparency I've heard. In the back half, we talk about his time at Altos Labs, why biology is a reality check for the "cure all disease in 10 years" claims, and his cell annealing theory of rejuvenation.

Key Takeaways

Thore sees AI progress as a "jagged frontier," not a single superintelligence moment, and by his own definition, AGI is already here

He argues companies and institutions are already a form of superintelligence

His P(doom) is very low: extraordinary claims require extraordinary evidence, and he doesn't see it

About Thore Graepel

Thore Graepel is a computer scientist and AI researcher who recently left Google DeepMind, where he was a co-creator of AlphaGo and worked on multi-agent s…
Dr Mike Israetel: ‘’ALMOST EVERY American Should Be On GLP-1s, Here’s Why!’’

24 september 2026 · 1 uur 52 min
Afspelen

What if vanity was actually the smart way into a longer, healthier life? Lees meer

This episode is brought to you by AgelessRx, where aging becomes a puzzle that can be solved. Their mission is to help you live longer and healthier by adding more life to your years through science-backed solutions and personalized care. Learn more at agelessrx.com/beyond-tomorrow.

On this episode of Beyond Tomorrow, Dr. Mike Israetel breaks down what's actually happening in his own bloodstream: 5mg/week of tirzepatide year-round, plus retatrutide during fat-loss phases, and why he thinks “GLP-2” is a gray-market marketing term with no basis in real receptor biology.

He walks through the non-weight-loss case for these drugs, reduced systemic and neural inflammation, better glucose control, emerging anti-cancer data, and a documented drop in addictive behaviors from gambling to alcohol to cigarettes, before getting honest about the tradeoffs: undernutrition, anhedonia, and a long-term data set that, by his own admission, will never be “complete enough” for some critics.

From there the conversation moves into gray-market peptides, why Mike separates his own risk tolerance from what he'd recommend to the public, and why there currently isn't a single peptide he'd recommend for muscle growth despite the demand. The back half covers his real thesis: that appearance, not health, is the most reliable motivator most people actually respond to and that chasing it tends to produce the same outcomes doctors have failed for decades to sell through fear.

Key Takeaways

Mike takes tirzepatide (Zepbound/Mounjaro) year-round at 5mg/week and adds retatrutide during cutting phases, both well within studied dose ranges

He argues most GLP-1 “anhedonia” is caloric-deficit anhedonia, not a direct drug effect, the same thing bodybuilders experience on any aggressive diet

New aggregate mortality data shows older adults on GLP-1s die less than those who aren't, which he says partially answers the “but will it …